Daniel R. Couriel
( out of 28 reviews )

Daniel R. Couriel, MD, MS, MBA

Languages spoken: Spanish, English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

4K, Hematology Inpatient
Salt Lake City
801-646-9500

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-6906

  • Dr. Couriel is an Endowed Chair recipient and a Tenured Associate Professor in the Division of Hematology and Hematologic Malignancies with the Department of Internal Medicine, at the University of Utah. He received his MBA in 2021 from the University of Utah Eccles School of Business.

    In 1987 he received his M.D. degree at the Universidad de Buenos Aires in Argentina. After fellowship training at Tufts University, NHLBI and Johns Hopkins University, he was appointed as Assistant Professor of Medicine at the University of Alabama Birmingham. In 1999 he moved to the M.D Anderson Cancer Center with the Department of Blood and Marrow Transplantation. He was promoted to Associate Professor in 2005, and relocated in 2010 to the Sarah Cannon Blood and Marrow Transplant Program in Nashville, TN. He was appointed as Director of the Allogeneic Transplant Program. In 2010 he moved to the University of Michigan Medical School where he served as a Clinical Professor and Director of the Adult Blood and Marrow Transplantation Program.

    Dr. Couriel has a history of consistent funding and has more than 100 peer reviewed journal articles. His research interests are associated with new treatments and biomarkers for acute and chronic graft-versus-host disease. He serves on the Editorial Board with Biology of Blood and Marrow Transplantation journal, he co-chairs the GVHD subcommittee for the CIBMTR, and the Ancillary and Supportive Care committee of a NIH Consensus Project on Chronic GVHD. He is the Medical Director for the Center of Cellular Therapy and Regenerative Medicine (CTRM) at the Huntsman Cancer Institute and the Director of the Utah Blood and Marrow Transplantation Program. He currently sits on the Board of Directors with the American Society of Cellular Therapy and Transplantation (ASTCT), and the Foundation for Accreditation of Cellular Therapy (FACT).

    Specialties

    Patient Rating

    4.9 /5
    ( out of 28 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 09, 2024
    HUNTSMAN CANCER CENTER

    Amazing! The entire team is simply amazing. Today I am cancer free, and I feel like the luckiest guy in the world. I'm so happy I found the Huntsman Cancer Center.

    October 06, 2024
    HUNTSMAN CANCER CENTER

    Very smart doctor. He has been a life saver in my life. I can't thank him enough for the great care he has given me.

    October 01, 2024
    HUNTSMAN CANCER CENTER

    Listens carefully and is very knowledgeable. He addressed all of my concerns in a way that I could easily understand.

    September 29, 2024
    HUNTSMAN CANCER CENTER

    Dr Couriel was very informative and answered my questions immediately. He also explained the procedure we are considering and the steps to accomplish it. I felt listened to, and cared for, at my first visit to his office.

    September 20, 2024
    HUNTSMAN CANCER CENTER

    Dr. Couriel and his Team are amazing and the procedure they did for me was Life saving...

    September 05, 2024
    HUNTSMAN CANCER CENTER

    He is a wonderful doctor that knows his profession well, and really cares for his patients

    June 07, 2024
    HUNTSMAN CANCER CENTER

    Dr Couriel not only provides excellent medical care but he also gives his patients hope. That is a very positive thing when dealing with cancer.

    June 06, 2024
    HUNTSMAN CANCER CENTER

    We are so very blessed to have him as our physician

    June 04, 2024
    HUNTSMAN CANCER CENTER

    Dr. Couriel was very knowledgeable and courteous.

    See More Patient Comments

  • Dr. Couriel is an Endowed Chair recipient and a Tenured Associate Professor in the Division of Hematology and Hematologic Malignancies with the Department of Internal Medicine, at the University of Utah. He received his MBA in 2021 from the University of Utah Eccles School of Business.

    In 1987 he received his M.D. degree at the Universidad de Buenos Aires in Argentina. After fellowship training at Tufts University, NHLBI and Johns Hopkins University, he was appointed as Assistant Professor of Medicine at the University of Alabama Birmingham. In 1999 he moved to the M.D Anderson Cancer Center with the Department of Blood and Marrow Transplantation. He was promoted to Associate Professor in 2005, and relocated in 2010 to the Sarah Cannon Blood and Marrow Transplant Program in Nashville, TN. He was appointed as Director of the Allogeneic Transplant Program. In 2010 he moved to the University of Michigan Medical School where he served as a Clinical Professor and Director of the Adult Blood and Marrow Transplantation Program.

    Dr. Couriel has a history of consistent funding and has more than 100 peer reviewed journal articles. His research interests are associated with new treatments and biomarkers for acute and chronic graft-versus-host disease. He serves on the Editorial Board with Biology of Blood and Marrow Transplantation journal, he co-chairs the GVHD subcommittee for the CIBMTR, and the Ancillary and Supportive Care committee of a NIH Consensus Project on Chronic GVHD. He is the Medical Director for the Center of Cellular Therapy and Regenerative Medicine (CTRM) at the Huntsman Cancer Institute and the Director of the Utah Blood and Marrow Transplantation Program. He currently sits on the Board of Directors with the American Society of Cellular Therapy and Transplantation (ASTCT), and the Foundation for Accreditation of Cellular Therapy (FACT).

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies

    Education history

    Graduate Training Business and Health Administration - University of Utah Eccles School of Business MBA
    Biostatistics and Clinical Research - University of Michigan School of Public Health M.Med.Sci.
    Residency Internal Medicine - George Washington University Hospital Resident
    Hematology - National Heart, Lung, and Blood Institute Fellow
    Fellowship Bone Marrow Transplantation Unit - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Fellow
    Leukemia Unit - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Fellow
    Fellowship Hematology/Oncology - St. Elizabeth’s Medical Center, Tufts University School of Medicine Fellow
    Internal Medicine - University of Buenos Aires Resident
    Professional Medical Medicine - University of Buenos Aires School of Medicine M.D.

    Selected Publications

    Journal Article

    1. Mercadal S, Mussetti A, Lee CJ, Arevalo C, Odstrcil SM, Pea E, Sureda A, Couriel DR (2024). Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature. Ann Hematol. (Read full article)
    2. Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Badawy SM, Bhatt N, Bhatt VR, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Hashmi S, Hematti P, Hossain NM, Inamoto Y, Lekakis LJ, Sharma A, Solomon S, Lee SJ, Couriel DR (2023). Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplant Cell Ther. (Read full article)
    3. Gomez-Lumbreras A, Mercadal Vilchez S, Villa-Zapata L, Malone DC, Couriel DR (2023). Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias. Leuk Lymphoma, 1-10. (Read full article)
    4. Mercadal S, Gomez CA, Lee CJ, Couriel DR (2023). Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature. Ann Hematol. (Read full article)
    5. Trunk AD, Radwanski K, Heber C, Taylor A, Hsieh F, Harris A, Lee CJ, Phillips JD, Couriel DR (2023). Impact of Cryopreservation on Extracorporeal Photopheresis (ECP)-Treated Leukocyte Subsets. Transplant Cell Ther. (Read full article)
    6. Saad A, Loren A, Bolaos-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Dabaja MK, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA (2023). Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw, 21(2), 108-115. (Read full article)
    7. Mercadal S, Gomez C, Lee C, Couriel DR (2022). "Infectious Complications Following Car-T Cell Therapy for B Cell Non-Hodgkin Lymphoma: A Single-Center Experience and Review of the Literature". Res Sq.
    8. Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, Badawy SM, Bhatt N, Bhatt VR, Cahn JY, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Gale RP, Hashem H, Hashmi S, Hematti P, Hong S, Hossain NM, Inamoto Y, Lekakis LJ, Modi D, Patel S, Sharma A, Solomon S, Couriel DR (2022). Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther, 28, 712.e1-712.e8. (Read full article)
    9. DePriest BP, Li H, Bidgoli A, Onstad L, Couriel DR, Lee SJ, Paczesny S (2022). Regenerating Islet-Derived 3-alpha is a Prognostic Biomarker for Gastrointestinal Chronic Graft-Versus-Host Disease. Blood Adv, 6, 2981-2986. (Read full article)
    10. Wolff D, Radojcic V, Lafyatis R, Cinar R, Rosenstein RK, Cowen EW, Cheng GS, Sheshadri A, Bergeron A, Williams KM, Todd JL, Teshima T, Cuvelier GDE, Holler E, McCurdy SR, Jenq RR, Hanash AM, Jacobsohn D, Santomasso BD, Jain S, Ogawa Y, Steven P, Luo ZK, Dietrich-Ntoukas T, Saban D, Bilic E, Penack O, Griffith LM, Cowden M, Martin PJ, Greinix HT, Sarantopoulos S, Socie G, Blazar BR, Pidala J, Kitko CL, Couriel DR, Cutler C, Schultz KR, Pavletic SZ, Lee SJ, Paczesny S (2021). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transplant Cell Ther, 27(10), 817-835. (Read full article)
    11. DeFilipp Z, Couriel DR, Lazaryan A, Bhatt VR, Buxbaum NP, Alousi AM, Olivieri A, Pulanic D, Halter JP, Henderson LA, Zeiser R, Gooley TA, MacDonald KPA, Wolff D, Schultz KR, Paczesny S, Inamoto Y, Cutler CS, Kitko CL, Pidala JA, Lee SJ, Socie G, Sarantopoulos S, Pavletic SZ, Martin PJ, Blazar BR, Greinix HT (2021). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplant Cell Ther, 27(9), 729-737. (Read full article)
    12. Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM (2021). Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant, 56(6), 1316-1324. (Read full article)
    13. Christensen A, Hsieh F, Boyer M, Couriel D, Reems JA (2020). Red Cell Depletion of Major ABO Incompatible Bone Marrow Hematopoietic Progenitor Cells HPC(M) with the Spectra Optia®. Ann Clin Lab Sci, 50(6), 781-789. (Read full article)
    14. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn JY, Weisdorf DJ (2020). Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol, 38(18), 2062-2076. (Read full article)
    15. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L (2020). Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(5), 599-634. (Read full article)
    16. Barnes CA, Stout NL, Varghese TK Jr, Ulrich CM, Couriel DR, Lee CJ, Noren CS, LaStayo PC (2019). Clinically Integrated Physical Therapist Practice in Cancer Care: A New Comprehensive Approach. Phys Ther, 100(3), 543-553. (Read full article)
    17. Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryan A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S (2019). Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant, 25(9), 1875-1883. (Read full article)
    18. Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Soci G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S (2019). Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 25(9), 1744-1755. (Read full article)
    19. DSouza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A (2019). A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant, 25(8), 1492-1497. (Read full article)
    20. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ (2018). GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv, 3(9), 1441-1449. (Read full article)
    21. Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ (2018). Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biol Blood Marrow Transplant, 25(2), 270-278. (Read full article)
    22. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK (2018). Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant, 25(1), 73-85. (Read full article)
    23. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR (2018). Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant, 25(1), 12-18. (Read full article)
    24. Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C, GV12-02 Writing Committee on behalf of the CIBMTR Graft-versus-Host Disease Working Committee (2018). Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica, 103(10), 1708-1719. (Read full article)
    25. Radojcic V, Lee CJ, Couriel DR (2018). Multifaceted Burden of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant, 24(9), 1774-1775. (Read full article)
    26. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, OBrien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR (2018). Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant, 53(7), 932-937. (Read full article)
    27. Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW (2018). Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Adv, 2(9), 1022-1031. (Read full article)
    28. MacDonald KPA, Betts BC, Couriel D (2018). Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant, 24(3S), S7-S14. (Read full article)
    29. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J (2018). Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant, 24(3), 521-528. (Read full article)
    30. MacDonald KPA, Betts BC, Couriel D (2018). Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant, 24(1), 19-26. (Read full article)
    31. Votruba KL, Hoodin F, Giordani B, Kentor R, Couriel DR, Kitko CL (2017). Prospective computerized monitoring of cognitive functioning before and after blood and marrow transplantation. Bone Marrow Transplant, 52(8), 1215-1217. (Read full article)
    32. Krakow EF, Hemmer M, Wang T, Logan B, Arora M, Spellman S, Couriel D, Alousi A, Pidala J, Last M, Lachance S, Moodie EEM (2017). Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. Am J Epidemiol, 186(2), 160-172. (Read full article)
    33. Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR (2017). B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. Bone Marrow Transplant, 52(7), 1010-1015. (Read full article)
    34. Miceli MH, Churay T, Braun T, Kauffman CA, Couriel DR (2017). Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients. Mycopathologia, 182(5-6), 495-504. (Read full article)
    35. Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J (2017). Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica, 102(5), 958-966. (Read full article)
    36. Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS (2016). GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant, 52(3), 400-408. (Read full article)
    37. Miller HK, Braun TM, Stillwell T, Harris AC, Choi S, Connelly J, Couriel D, Goldstein S, Kitko CL, Magenau J, Pawarode A, Reddy P, Riwes M, Yanik GA, Levine JE (2017). Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant, 23(3), 522-528. (Read full article)
    38. Syed FI, Couriel DR, Frame D, Srinivasan A (2016). Central Nervous System Complications of Hematopoietic Stem Cell Transplant. Hematol Oncol Clin North Am, 30(4), 887-98. (Read full article)
    39. Couriel DR, Ricker H, Steinbach M, Lee CJ (2016). Neurologic Manifestations of Blood Dyscrasias. Hematol Oncol Clin North Am, 30(4), 723-31. (Read full article)
    40. Kitko CL, Braun T, Couriel DR, Choi SW, Connelly J, Hoffmann S, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik GA, Ferrara JL, Levine JE (2015). Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant, 22(5), 862-8. (Read full article)
    41. Kitko CL, Braun T, Couriel DR, Choi SW, Connelly J, Hoffmann S, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik GA, Ferrara JL, Levine JE (2016). Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant, 22(5), 862-8. (Read full article)
    42. Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW (2016). FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant, 51(4), 511-520. (Read full article)
    43. Zhu L, Couriel DR, Chang CH (2016). The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leuk Lymphoma, 57(2), 376-384. (Read full article)
    44. Zhou C, Chan HP, Dong Q, Couriel DR, Pawarode A, Hadjiiski LM, Wei J (2015). Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study. Radiology, 278(2), 449-57. (Read full article)
    45. Zhou C, Chan HP, Dong Q, Couriel DR, Pawarode A, Hadjiiski LM, Wei J (2015). Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study. Radiology, 278(2), 449-57. (Read full article)
    46. Zhu L, Couriel DR, Chang CH (2015). The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leuk Lymphoma, 57(2), 376-384. (Read full article)
    47. Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR (2016). Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant, 22(1), 54-60. (Read full article)
    48. Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdn OT, Soci G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ (2015). Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Transplant, 21(10), 1776-82. (Read full article)
    49. Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW, Savani BN, Schultz KR, Smith SR, Syrjala KL, Treister N, Vogelsang GB, Williams KM, Pavletic SZ, Martin PJ, Lee SJ, Couriel DR (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant, 21(7), 1167-87. (Read full article)
    50. Miceli MH, Perissinotti AJ, Kauffman CA, Couriel DR (2015). Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses, 58(7), 432-6. (Read full article)
    51. Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, DiPersio JF (2015). [18F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther, 23(6), 1110-1122. (Read full article)
    52. Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, DiPersio JF (2015). [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther, 23(6), 1110-1122. (Read full article)
    53. Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC (2015). Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol, 94(6), 1033-41. (Read full article)
    54. Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR (2015). Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant, 21(6), 1127-31. (Read full article)
    55. Smith SR, Haig AJ, Couriel DR (2015). Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant, 21(5), 799-808. (Read full article)
    56. Radojcic V, Pletneva MA, Couriel DR (2015). The role of extracorporeal photopheresis in chronic graft-versus-host disease. Transfus Apher Sci, 52(2), 157-61. (Read full article)
    57. Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME (2015). Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transplant, 21(4), 640-5. (Read full article)
    58. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdn OT, Savani BN, Soci G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Prez-Simn JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the CIBMTR (2015). Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant, 21(2), 266-74. (Read full article)
    59. Caram MV, Bellile EL, Englesbe MJ, Terjimanian M, Wang SC, Griggs JJ, Couriel D (2015). Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. Leuk Lymphoma, 56(10), 2855-62. (Read full article)
    60. Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, Levine JE, Morgan S, Schneiderman J, Sloan S, Wu Y, Szczepiorkowski ZM, Cooling L, American Society for Apheresis (2015). National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. Transfus Med Rev, 29(1), 62-70. (Read full article)
    61. Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE (2015). Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant, 21(1), 55-9. (Read full article)
    62. Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DR (2014). Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant, 20(12), 2062-6. (Read full article)
    63. Galbn CJ, Boes JL, Bule M, Kitko CL, Couriel DR, Johnson TD, Lama V, Telenga ED, van den Berge M, Rehemtulla A, Kazerooni EA, Ponkowski MJ, Ross BD, Yanik GA (2014). Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 20(10), 1592-8. (Read full article)
    64. Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW (2014). Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 20(9), 1426-34. (Read full article)
    65. Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Couriel DR, Martin PJ, Flowers ME, Hansen JA, Chang L, Conlon M, Fiema BJ, Morgan R, Pongtornpipat P, Lamiman K, Ferrara JL, Lee SJ, Paczesny S (2014). Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood, 123(5), 786-93. (Read full article)
    66. Choi SW, Braun T, Chang L, Ferrara JLM, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P (2014). Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: A phase 1/2 trial. Lancet Oncol, 15(1), 87-95. (Read full article)
    67. Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P (2014). Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol, 15(1), 87-95. (Read full article)
    68. Magenau J, Couriel DR (2013). Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how. Curr Oncol Rep, 15(5), 436-44. (Read full article)
    69. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S (2013). ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med, 369(6), 529-39. (Read full article)
    70. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE (2013). Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica, 98(2), 179-84. (Read full article)
    71. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JLM, Paczesny S (2013). ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med, 369(6), 529-539. (Read full article)
    72. Harris AC, Kitko CL, Couriel DR (2013). Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Transfuze a Hematologie Dnes, 19(2), 119. (Read full article)
    73. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120(9), 1801-9. (Read full article)
    74. Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ (2012). Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma, 53(5), 915-9. (Read full article)
    75. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M (2012). Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma, 53(5), 901-6. (Read full article)
    76. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy P, Paczesny S (2012). Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood, 119(12), 2960-3. (Read full article)
    77. Blazar B, White ES, Couriel D (2012). Understanding chronic GVHD from different angles. Biol Blood Marrow Transplant, 18(1 Suppl), S184-8. (Read full article)
    78. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AM (2012). Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant, 47(1), 125-31. (Read full article)
    79. Westin J, Saliba R, De Lima M, Alousi A, Hosing C, Qazilbash M, Khouri I, Shpall E, Anderlini P, Rondon G, Andersson B, Champlin R, Couriel D (2011). Steroid-refractory acute GVHD: Predictors and outcomes. Adv Hematol, 2011. (Read full article)
    80. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U (2011). High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol, 86(11), 954-6. (Read full article)
    81. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ (2011). Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol, 29(3), 294-302. (Read full article)
    82. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR (2011). Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol, 2011, 601953. (Read full article)
    83. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ (2011). Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 17(1), 124-32. (Read full article)
    84. Cheng YC, Rondn G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT (2009). Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol, 90(5), 627-634. (Read full article)
    85. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A (2009). A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant, 15(12), 1555-62. (Read full article)
    86. Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q (2009). Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant, 15(12), 1513-22. (Read full article)
    87. Knobler R, Barr ML, Couriel DR, Ferrara JL, French LE, Jaksch P, Reinisch W, Rook AH, Schwarz T, Greinix H (2009). Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol, 61(4), 652-65. (Read full article)
    88. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M (2009). Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant, 43(9), 685-92. (Read full article)
    89. Joseph RW, Couriel DR, Komanduri KV (2008). Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. J Support Oncol, 6(8), 361-72. (Read full article)
    90. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE (2008). Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 111(12), 5530-6. (Read full article)
    91. Couriel DR (2008). Ancillary and supportive care in chronic graft-versus-host disease. Best Pract Res Clin Haematol, 21(2), 291-307. (Read full article)
    92. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE (2008). Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant, 14(6), 672-84. (Read full article)
    93. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I (2008). High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol, 19(6), 1166-71. (Read full article)
    94. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ (2008). Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant, 41(9), 771-8. (Read full article)
    95. Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR, Lee JH, Couriel D (2008). Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol, 103(4), 982-9. (Read full article)
    96. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE (2008). Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 93(2), 257-64. (Read full article)
    97. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S (2008). Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia, 22(2), 258-64. (Read full article)
    98. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, Safdar A, Broglio KR, Adachi R, Dickey BF (2008). Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant, 41(1), 63-7. (Read full article)
    99. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M (2007). Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood, 110(9), 3456-62. (Read full article)
    100. Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF (2007). Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant, 40(5), 431-5. (Read full article)
    101. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA (2007). Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant, 13(9), 1066-72. (Read full article)
    102. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV (2007). Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant, 40(2), 125-36. (Read full article)
    103. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M (2007). Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant, 13(4), 454-62. (Read full article)
    104. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR (2007). Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood, 109(7), 2751-8. (Read full article)
    105. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR (2007). A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood, 109(6), 2657-62. (Read full article)
    106. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA (2007). Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant, 39(5), 279-83. (Read full article)
    107. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, Pierre B, Shpall EJ, Jones RB, Champlin RE, Andersson BS (2007). Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant, 13(1), 56-64. (Read full article)
    108. Hymes SR, Turner ML, Champlin RE, Couriel DR (2006). Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 12(11), 1101-13. (Read full article)
    109. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M (2006). Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant, 38(6), 421-6. (Read full article)
    110. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S (2006). Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant, 38(4), 299-303. (Read full article)
    111. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF (2006). Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant, 38(3), 203-9. (Read full article)
    112. Hosing C, Saliba RM, Krbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML (2006). High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma, 47(7), 1290-4. (Read full article)
    113. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M (2006). Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood, 107(8), 3074-80. (Read full article)
    114. Gupta S, Jain A, Fanning TV, Couriel DR, Jimenez CA, Eapen GA (2006). An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report. BMC Cancer, 6, 87. (Read full article)
    115. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB, Response Criteria Working Group (2006). Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant, 12(3), 252-66. (Read full article)
    116. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA (2006). Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer, 106(5), 1084-9. (Read full article)
    117. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ (2006). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant, 12(2), 126-37. (Read full article)
    118. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R (2006). Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant, 12(1 Suppl 2), 37-40. (Read full article)
    119. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 11(12), 945-56. (Read full article)
    120. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R (2005). Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol, 80(1), 43-5. (Read full article)
    121. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R (2005). Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol, 130(3), 409-17. (Read full article)
    122. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M (2005). Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant, 36(2), 157-62. (Read full article)
    123. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE (2005). Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol, 23(10), 2240-7. (Read full article)
    124. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S (2005). Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant, 11(2), 108-14. (Read full article)
    125. Couriel D, Caldera H, Champlin R, Komanduri K (2004). Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer, 101(9), 1936-46. (Read full article)
    126. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D (2004). Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant, 10(10), 655-68. (Read full article)
    127. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE (2004). Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant, 34(6), 511-4. (Read full article)
    128. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S (2004). Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood, 104(3), 865-72. (Read full article)
    129. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS (2004). Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 104(3), 857-64. (Read full article)
    130. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R (2004). Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood, 104(3), 649-54. (Read full article)
    131. El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Giralt S, Khouri I, Ippoliti C, Champlin R, de Lima M (2004). Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood, 103(12), 4674-80. (Read full article)
    132. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R (2004). Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant, 10(3), 178-85. (Read full article)
    133. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV (2004). CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood, 103(3), 1140-6. (Read full article)
    134. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE (2004). Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol, 32(1), 28-35. (Read full article)
    135. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE (2003). Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 102(10), 3829-36. (Read full article)
    136. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M (2003). Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood, 102(8), 3052-9. (Read full article)
    137. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, Brunvand MM, Martin PJ, Bertz H, Clark R, Couriel DR, Gore SD, De Lima M, Morgenstern G, Parker A, Thiel E, Zamkoff KW (2003). A phase III, randomized, double-blind, placebo-controlled, multinational trial of Iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT Trial). Leuk Lymphoma, 44(7), 1165-1172. (Read full article)
    138. Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D (2003). Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol, 122(1), 128-34. (Read full article)
    139. Wong R, de Lima M, Couriel D, Giralt S, Hosing C, Shahjahan M, Cheng YC, Bruton J, Champlin R, Khouri I (2003). Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab. Leuk Lymphoma, 44(5), 829-32. (Read full article)
    140. Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P (2003). Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant, 31(6), 459-65. (Read full article)
    141. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H (2003). Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer, 97(5), 1242-7. (Read full article)
    142. De Lima M, St John LS, Wieder ED, Lee MS, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Bibawi S, Champlin R, Komanduri KV (2002). Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol, 119(3), 773-6. (Read full article)
    143. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Krbling M, Martin T, Ueno NT, Champlin RE, Khouri IF (2002). Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol, 13(3), 450-9. (Read full article)
    144. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE (2002). Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant, 8(9), 477-85. (Read full article)
    145. Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, Horowitz MM, Akpek G, Flowers ME, Couriel D, Martin PJ (2002). A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant, 8(1), 32-9. (Read full article)
    146. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF (2001). Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol, 19(17), 3766-70. (Read full article)
    147. Couriel DR, Hicks K, Giralt S, Champlin RE (2000). Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol, 12(6), 582-7. (Read full article)
    148. Gonzalez CE, Couriel DR, Walsh TJ (1997). Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis, 24(2), 192-6. (Read full article)
    149. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J (1996). CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood, 88(8), 3223-9. (Read full article)
    150. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ (1996). Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant, 18(2), 347-53. (Read full article)
    151. Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J, Barrett AJ (1996). Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol, 93(3), 606-12. (Read full article)
    152. Mavroudis DA, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman RJ, Pastan I, Barrett AJ (1996). Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant, 17(5), 793-9. (Read full article)
    153. Jiang YZ, Couriel D, Mavroudis DA, Lewalle P, Malkovska V, Hensel NF, Dermime S, Molldrem J, Barrett AJ (1996). Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Immunology, 87(3), 481-6. (Read full article)
    154. Lewalle P, Hensel N, Guimaraes A, Couriel D, Jiang Y Z, Mavroudis D, Barrett AJ (1996). Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells. Br J Haematol, 92(3), 587-94. (Read full article)
    155. Couriel D, Weinstein R (1994). Complications of therapeutic plasma exchange: a recent assessment. J Clin Apher, 9(1), 1-5. (Read full article)

    Review

    1. Odstrcil MS, Lee CJ, Sobieski C, Weisdorf D, Couriel D (2023). Access to CAR T-cell therapy: Focus on diversity, equity and inclusion. [Review]. Blood Rev, 63, 101136. (Read full article)
    2. Fortune K, Couriel D (2009). Tacrolimus in hematopoietic stem cell transplantation. [Review]. Expert Opin Drug Metab Toxicol, 5(7), 835-41. (Read full article)
    3. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ (2007). Transplantation's greatest challenges: advances in chronic graft-versus-host disease. [Review]. Biol Blood Marrow Transplant, 13(1 Suppl 1), 2-10. (Read full article)
    4. Komanduri KV, Couriel D, Champlin RE (2006). Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. [Review]. Biol Blood Marrow Transplant, 12(1 Suppl 2), 1-6. (Read full article)
    5. Ross WA, Couriel D (2005). Colonic graft-versus-host disease. [Review]. Curr Opin Gastroenterol, 21(1), 64-9. (Read full article)
    6. Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, Anagnostopoulos A, Champlin R (2002). Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. [Review]. Bone Marrow Transplant, 30(8), 543-6. (Read full article)

    Book Chapter

    1. Kitko CL, Couriel DR (2014). Chronic Graft-Versus-Host Disease. In Kitko CL|Couriel DR (Ed.), Cancer Consult: Expertise for Clinical Practice (pp. 438-443). (Read full article)
    2. Kitko CL, Couriel DR (2014). Chronic Graft vs Host Disease. In Abutalib S, Markman M (Eds.), Cancer consult: expertise for clinical practice (pp. 438-447). Wiley Blackwell.
    3. Couriel D (2013). Diagnosis and treatment of graft-versus-host disease. In Couriel D (Ed.), The BMT Data Book: Including Cellular Therapy (pp. 311-329). (Read full article)
    4. Zureki K, Couriel DR (2012). ECP in Chronic GVHD: Steroid-Sparing Effect. In Zureki K|Couriel DR (Ed.), Extracorporeal Photopheresis: Cellular Photoimmunotherapy (pp. 122-127). (Read full article)
    5. Carpenter PA, Couriel DR (2009). General principles of ancillary and supportive care. In Carpenter PA|Couriel DR (Ed.), Chronic Graft Versus Host Disease: Interdisciplinary Management (pp. 157-166). (Read full article)
    6. Couriel D (2009). Diagnosis and treatment of graft-versus-host-disease. In Couriel D (Ed.), The BMT Data Book, 2nd Edition (pp. 331-356). (Read full article)
    7. Couriel DR (2009). Diagnosis and Treatment of Graft Versus Host Disease. In Munker R, Lazarus H, Atkinson K (Eds.), The BMT Data Book (pp. 331-56). Cambridge University Press.
    8. Carpenter PA, Couriel DR (2009). General Principles of Ancillary and Supportive Care. In Vogelsang GB, Pavletic SZ (Eds.), Chronic Graft Versus Host Disease: Interdisciplinary Management (pp. 157-68). Cambridge University Press.
    9. Ghosh S, Couriel DR (2005). Complications of Bone Marrow Transplantation and Immunosuppression. In Ghosh S|Couriel DR (Ed.), Acute Care of the Cancer Patient (pp. 697-711). (Read full article)
    10. Couriel DR, Sergio G (2005). Graft-Versus-Host Disease in Nonmyeloablative Transplant. In Ferrera J, Cooke K (Eds.), Graft-versus-Host Disease (pp. 511-23). New York: Marcel Dekker.
    11. Ghosh S, Couriel DR (2005). Complications of Immunosuppressive Treatment. In Perioperative Cancer Medicine: Anesthesia, Critical Care and Pain Control in Cancer Patients.
    12. Ghosh S, Couriel DR (2005). Complications of Bone Marrow Transplantation and Immunosuppression. In Shaw A, Riedel B, Burton A, Fields A, Freeley TW (Eds.), Acute Care of Cancer Patient (pp. 692-712). Informa Healthcare.

    Editorial

    1. Couriel DR (2015). Bio: Daniel R. Couriel, MD. Transfus Apher Sci, 52(2), 148. (Read full article)
    2. Couriel DR (2015). Extracorporeal photopheresis: Focus on therapeutic immunomodulation. Transfus Apher Sci, 52(2), 149-50. (Read full article)
    3. Couriel DR (2015). Extracorporeal photopheresis: Focus on therapeutic immunomodulation. Transfus Apher Sci, 52(2), 149-50. (Read full article)
    4. Khanna D, Georges GE, Couriel DR (2014). Autologous hematopoietic stem cell therapy in severe systemic sclerosis: ready for clinical practice? JAMA, 311(24), 2485-7. (Read full article)

    Letter

    1. Trunk AD, Shewan SK, Lee CJ, Parker CJ, Couriel DR (2022). Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination. [Letter to the editor]. Bone Marrow Transplant, 57(3), 502-503. (Read full article)
    2. Radojcic V, Pletneva M, Lee CJ, Ivcevic S, Sarantopoulos S, Couriel D (2021). Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease. [Letter to the editor]. Br J Haematol, 195(2), e120-e122. (Read full article)
    3. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M (2017). Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. [Letter to the editor]. Br J Haematol, 182(6), 916-920. (Read full article)
    4. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ (2014). Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. [Letter to the editor]. Haematologica, 99(9), e162-4. (Read full article)
    5. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M (2007). Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. [Letter to the editor]. Leukemia, 21(12), 2540-4. (Read full article)
    6. Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE (2003). Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. [Letter to the editor]. Biol Blood Marrow Transplant, 9(11), 722-4. (Read full article)
    7. Wong R, Couriel D, Prieto VG (2003). The graft-versus-leukemia effect in leukemia cutis. [Letter to the editor]. Transplantation, 76(3), 619-20. (Read full article)

    Abstract

    1. Saad A, Loren A, Bolaos-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA (2023). NCCN Guidelines Insights: Hematopoietic Cell Transplantation, Version 3.2022 [Abstract].
    2. Catherine J Lee, Tao Wang, Karen Chen, Stephen R Spellman, Carrie Lynn Kitko, Margaret L MacMillan, Joseph A Pidala, Jeffery J Auletta, Sherif Badawy, Minoo Battiwalla, Vijaya Raj Bhatt, David Buchbinder, Jean-Yves Cahn, Zachariah DeFilipp, Miguel Angel Diaz, Nosha Farhadfar, Shahinaz M Gadalla, Robert Peter Gale, Hasan Hashem, Shahrukh K Hashmi, Peiman Hematti, Sanghee Hong, Nasheed Hossain, Yoshihiro Inamoto, Rammurti T Kamble, Anita Kumar, Lazaros J Lekakis, Dipenkumar Modi, Sagar Patel, Bipin Savani, Akshay Sharma, Scott R Solomon, Leo Verdonck, Mukta Arora, Daniel R Couriel (2021). Impact of Chronic Graft-Versus-Host Disease on First late Effect Among Adult Survivors of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplantation Research (CIMBTR) Analysis [Abstract]. 27(3, Supplement), S39-S40.
    3. Erin Sweetser, Daniel Couriel, Catherine Lee, Christopher Barnes, Christopher Noren, Kayla Woodring, Ed Wicklander (2020). Functional Outcome measures in Hematopoietic Stem Cell Transplant (HSCT): Focus on the 2-Minute Walk Test. The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral session (O010-O173) [Abstract]. 55(Supplement 1), 22-174.
    4. Christopher Barnes, Catherine lee, Ryan Rushton, James Dane Osborn, Erin Sweetser, Jeramie Gaillard, Robin L Marcus, Christopher s Noreen, Paul Lastayo, Daniel Couriel (2019). Use of a Patient-Reported Physical Function Measure Allows Clinically-Pragmatic, Individually-Tailored Exercise Interventions for People with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: QUALITY MANAGEMENT GROUP - ORAL SESSION. [Abstract]. 53((Supplement 1)).
    5. Christopher A Barnes, Catherine J Lee, Ryan J Rushton, James Dane Osborn, Erin Sweetser, Jeramie Gaillard, Robin L Marcus, Christopher S Noren, Daniel R Couriel, Paul LaStayo (2018). - Assessing and Intervening to Improve Mobility for People with Post-Acute Hematopoietic Cell Transplant: A Quality Improvement Project [Abstract]. 24(3, Supplement), S307.
    6. Catherine J Lee, James Dane Osborn, Jonathan T Chapple, Michael Boyer, Axel Zander, Daniel R Couriel (2018). Impact of Geographic and Socioeconomic Factors (SEF) on Long-Term Hematopoietic Stem Cell Transplant (HSCT) Outcomes [Abstract]. 24(3, Supplement), S263-S264.
    7. Attaphol Pawarode, MD, Daniel R Couriel, MD, MS, Thomas Braun, PhD, John M Magenau, MD, Mary M Riwes, DO, Brian L Parkin, MD, Vedran Radojcic, MD, David Frame, PharmD, Sung Won Choi, MD, Pavan Reddy, MD, Steven C Goldstein, MD (2016). Phase 1 Study of Carfilzomib in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. [Abstract]. Biol Blood Marrow Transplant, 22(3), S346.
    8. Michael Boyer, MD, Pam Jacobson, James Marvin, Fen Fen Hsieh, Amber Preslar, Michael A Pulsipher, MD, Gerhard C Hildebrandt, MD, Axel Zander, MD, PhD, FACP, Daniel R Couriel, MD, MS, JoAnna Reems (2016). Reduced Intensity Haploidentical Stem Cell Transplantation with CD34 Selection and Addback of Regulatory and Conventional T Cells. [Abstract]. Biol Blood Marrow Transplant, 22(3), S379-S380.
    9. Steven C Goldstein, MD, John Koreth, MBBS, DPhil, John M Magenau, MD, Robert J Soiffer, MD, Thomas Braun, PhD, Maggi Kennel, BS, MS, Reaha Goyetche, Attaphol Pawarode, MD, Mary M Riwes, DO, Joseph H Antin, MD, Corey S Cutler, MD, MPH, Vincent T Ho, MD, Edwin P Alyea III, MD, Brian L Parkin, MD, Gregory A Yanik, MD, Sung Won Choi, MD, Daniel R Couriel, MD, MS, John E Levine, MD, MS, Vedran Radojcic, MD, Charles Dinarello, MD, Pavan Reddy, MD (2016). Alpha 1 Anti-Trypsin (AAT): Novel Strategy to Treat Steroid Refractory Acute Graft Versus Host Disease [Abstract]. Biol Blood Marrow Transplant, 22(3), S57.
    10. Christina AM Smith, Tracey L Churay, Holly A Justman, Jessica K Yu, Attaphol Pawarode, MD, David Hanauer, MS, MD, John Magenau, MD, Steven C Goldstein, MD, Mary Mansour Riwes, DO, Brian Parkin, MD, John Levine, MD, MS, Daniel R Couriel, MD, MS (2015). The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma. [Abstract]. Biol Blood Marrow Transplant, 21(2), S204-S205.
    11. Carrie L Kitko, MD, Thomas Braun, PhD, Charles Schuler, MD, Sung Won Choi, MD, Gregory Yanik, MD, Attaphol Pawarode, MD, John Magenau, MD, Austin Taylor, James LM Ferrara, MD, DSc, Daniel R Couriel, MD, MS, John Levine, MD, MS (2015). Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplantí [Abstract]. Biol Blood Marrow Transplant, 21(2), S337.
    12. Abedin S, Peres E, Levine JE, Yanik G, Pawarode A, Choi SW, Couriel DR (2014). Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using FluBu4/TLI [Abstract]. Biol Blood Marrow Transplant, 20(2), S211.
    13. Churay TL, Justman HA, Skurka NL, Goldstein SC, Pawarode A, Magenau J, Couriel DR (2014). The Impact of Mold Infections after Allogeneic Transplantation [Abstract]. Biol Blood Marrow Transplant, 20(2), S218.
    14. Raser K, McNulty ML, Yanik G, Goldstein SC, Magenau J, Pawarode A, Kitko CL, Hanauer D, Levine J, Couriel DR (2014). Routine Prophylaxis of Pneumocystis Jirovecii Pneumonia in Recipients of Autologous Hematopoietic Stem Cell Transplantation [Abstract]. Biol Blood Marrow Transplant, 20(2), S116-7.
    15. Pawarode A, Braun T, Magenau J, Choi SW, Kitko CL, Yanik G, Goldstein SC, Couriel DR (2014). Allogeneic Hematopoietic Cell Transplant (Allo-HCT) for Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma: The University of Michigan Experience [Abstract]. Biol Blood Marrow Transplant, 20(2), S76.
    16. Raser KJ, Yanik GA, Magenau JM, Goldstein SC, Pawarode A, Kitko CL, Levine JE, Hanauer D, Couriel DR (2013). Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study [Abstract]. Blood, 122(21), 3372.
    17. Arai S, Arora M, Wang T, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Spellman S, Pavletic SZ (2013). Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research [Abstract]. Blood, 122(21), 3309.
    18. Flowers MED, Hemmer MT, Li P, Cutler CS, Urbano-Ispizua A, Couriel DR, Gale RP, Inamoto Y, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman S, Weisdorf DJ, Pavletic, SZ, Lee SJ, Horowitz MM, Arora M (2013). The CIBMTR Chronic GVHD Risk Group Predicts Major Outcomes In An Independent Validation Cohort [Abstract]. Blood, 122(21), 706.
    19. Abedin S, Yanik GA, Magenau JM, Goldstein SC, Pawarode A, Levine JE, Kitko CL, Couriel DR (2013). Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients [Abstract]. Blood, 122(21), 2060.
    20. Vander Lugt M, Braun T, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel DR, Reddy P, Paczesny S (2013). Plasma ST2 Concentrations Predict Acute Gvhd Development and Non-Relapse Mortality [Abstract]. Biol Blood Marrow Transplant, 19(2, suppl), S142-3.
    21. Abedin S, Yanik G, Magenau J, Pawarode A, Goldstein SC, Kitko CL, White E, Couriel DR (2013). The Use of Early Spirometric Changes and IGF-1 Levels for the Detection of Patients at Risk for BOS [Abstract]. Biol Blood Marrow Transplant, 19(2), S316-7.
    22. Kitko CL, Saliba R, Paczesny S, Kennel M, Choi S, Reddy P, Levine J, Couriel DR (2013). Non-Relapse Mortality in Chronic Graft Versus Host Disease: Risk Factors At Onset and Reponse to Treatment [Abstract]. Biol Blood Marrow Transplant, 19(2), S332.
    23. Frame D, Beechuk R, Markstrom D, Magenau J, Couriel DR (2013). Vitamin D Supplementation Decreases Grade 3-4 Acute GVHD in Allogeneic Transplants with Normal Baseline Levels [Abstract]. Biol Blood Marrow Transplant, 19(2), S324.
    24. Pawarode A, Mineishi S, Braun T, Ferrara JLM, Magenau J, Peres E, Yanik G, Reddy P, Levine JE, Choi SW, Kitko CL, Harris AC, Connelly JA, Goldstein SC, Couriel DR (2013). Phase 2 Study of Allogeneic Hematopoietic Cell Transplant (HCT) Following Intermediate-Intensity Fludarabine and Busulfan x 4 (FluBu4) Conditioning for High-Risk or Advanced Multiple Myeloma [Abstract]. Biol Blood Marrow Transplant, 19(2), S238.
    25. Kitko CL, Saliba R, Choi SW, Reddy P, Goldstein SC, Magenau J, Pawarode A, Kennel M, Levine JE, White E, Couriel DR (2013). Biomarkers of Extracellular Matrix Remodeling in Chronic GVHD [Abstract]. Biol Blood Marrow Transplant, 19(2), S332.
    26. Caram MV, Bellile EL, Englesbe M, Terjimanian M, Sonnenday C, Griggs JJ, Couriel DR (2013). The Impact of Sarcopenia on Transplant-Related Outcomes in Patients with Non-Hodgkin's and Hodgkin's Lymphoma [Abstract]. Biol Blood Marrow Transplant, 19(2), S234.
    27. Magenau J, Pawarode A, Couriel DR, Yanik G, Mineishi S, Braun T, Reddy P, Ferrara JLM, Frame D, Choi SW, Harris AC, Kitko CL, Connelly JA, Levine J, Goldstein SC (2013). Impact of Dose Intensification of FluBu2 to FluBu4 on Transplant Related Mortality, Relapse, and Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia in Remission [Abstract]. Biol Blood Marrow Transplant, 19(2), S226.
    28. Yanik G, Magenau J, Goldstein SC, Pawarode A, Talpaz M, Levine J, Choi S, Kitko CL, Couriel DR (2013). A Prospective Study of Allogeneic Transplant for Older Patients with Acute Myelogenous Leukemia (AML) Indicates that Unrelated Donor Transplants are as Efficacious as Related Donor, with Favorable Outcomes for Intermediate Risk Disease [Abstract]. Biol Blood Marrow Transplant, 19(2), S232.
    29. Harris AC, Ferrara JLM, Braun T, Couriel DR, Choi S, Kitko CL, Goldstein SC, Magenau J, Paczesny S, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly JA, Byersdorfer CA, Levine JE (2013). A Combination of Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation From Related Donors [Abstract]. Biol Blood Marrow Transplant, 19(2), S138-9.
    30. Vander Lugt M, Braun TM, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine J, Choi S, Couriel D, Reddy P, Paczesny S (2012). Plasma ST2 Concentrations Predict Development of Acute Gvhd and Non-Relapse Mortality [Abstract]. Blood, 120(21), 466.
    31. Harris AC, Ferrara JLM, Braun TM, Couriel D, Choi S, Kitko C, Goldstein S, Magenau J, Paczesny P, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly JA, Byersdorfer CA, Levine J (2012). An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation [Abstract]. Blood, 120(21), 463.
    32. Yanik G, Magenau J, Mineishi S, Pawarode A, Alangaden K, Peres E, Goldstein S, Levine J, Choi S, Kitko C, Talpaz M, Couriel D (2012). Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease [Abstract]. Blood, 120(21), 3119.
    33. Choi S, DiPersio J, Braun T, Goldstein KS, Tawara I, Levine J, Sun Y, Couriel D, Krijanovski O, Chang L, Magenau J, Pawarode A, Kitko C, Paczesny S, Peres E, Mineishi S, Yanik GA, Lehmann M, Dinarello CA, Ferrara JLM, Reddy P (2012). Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention [Abstract]. Blood, 120(21), 740.
    34. Kitko C, Saliba RM, Paczesny S, Kennel M, Choi S, Reddy P, Levine J, Couriel D (2012). Risk Factors for Non-Relapse Mortality in Chronic Graft Versus Host Disease: Predicting Outcomes At Disease Onset [Abstract]. Blood, 120(21), 1941.
    35. Berdeja JG, Couriel DR, Murphy P, Boccia RV, Priego V, Hainsworth JD, Macias-Perex IM, Flinn IW (2011). A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis [Abstract]. Blood, 118(21), 2943.
    36. Vander Lugt MT, Braun T, Ferrara JLM, Hanash S, Levine JE, Wang CH, Zhang Q, Chin A, Harris AC, Choi SWJ, Couriel D, Reddy P, Paczesny S (2011). Plasma Concentration of ST2, the IL33 Receptor, At Initiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment [Abstract]. Blood, 118(21), 152.
    37. Jakubowiak AJ, Dytfeld D, Jagannath S, Vesole DH, Anderson TA, Nordgren BK, Detweiler-Short K, Lebovic D, Stockerl-Ott KE, Griffith KA, Jobkar TL, Durecki DE, Wear SM, Ott RF, Al-Zoubi A, Mietzel MA, Hussein M, Couriel D, Leveque JA, Vij R (2011). Final Results of a Frontline Phase ½ Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM) [Abstract]. Blood, 118(21), 634.
    38. Lee SJ, Flowers ME, Martin PJ, Carpenter P, Hansen J, Chai X, Kurland B, Storer B, Arai S, Johnston L, Miklos D, Weisdorf D, Arora M, Majhail N, Cutler C, Jagasia M, Palmer J, Pidala J, Westervelt P, Pusic I, Giralt S, Goldberg J, Couriel D, Kitko C, Jacobsohn D, Pavletic SZ, Vogelsang GB, Gilman A, Schultz K (2011). Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD [Abstract]. Biol Blood Marrow Transplant, 17(8), 1114-20.
    39. Cooling L, Hoffmann S, Mineishi S, Couriel D (2011). High-Dose Cytarabine for Mobilization and Collection of Autologous Hematopoietic Progenitor Cells [Abstract]. American Society for Apheresis Annual Meeting.
    40. Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi S, Kitko C, Magenau J, Yanik G, Peres E, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel D, Reddy P, Hanash S, Ferrara J, Levine J (2010). Three biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease [Abstract]. Blood, 116(21), 675.
    41. Williams L, Couriel D, Mendoza T, McCarthy P, Neumann J, White M, Mobley G, Kapoor S, Hernandez L, Alousi A, Cleeland C (2010). A New Measure of Symptom Burden in Chronic Graft-Versus-Host Disease [Abstract]. Biol Blood Marrow Transplant, 16(2), S177.
    42. Garcia-Manero G, Couriel DR, Tambaro FP, Gabrail N, Nadeem A, Kadia T, Jabbour E, Bathakur G, Faderl S, Newsome WM, Yang H, Stein K, Chen K, Kantarjian H (2009). A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times. Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS) [Abstract]. Blood, 114(22), 119.
    43. Joseph RW, Jr, Komanduri KV, Saliba RM, Alousi A, Giralt S, Rondon G, Neumann J, Trevino C, Couriel DR, Champlin R, Popat U (2008). High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients [Abstract]. Blood, 112(11), 2138.
    44. Williams LA, Neumann JL, Couriel DR, Mendoza TR, White MH, Zhang Y, Cleeland CS (2008). Measuring the Symptom Burden of Chronic Graft Versus Host Disease [Abstract]. Biol Blood Marrow Transplant, 14(2), 56.
    45. Williams LA, Couriel DR, Neumann JL, Whisenant MS, Galbizo EO, Cleeland CS (2008). Defining the Symptom Burden of Chronic Graft Versus Host Disease [Abstract]. Biol Blood Marrow Transplant, 14(2), 164-5.
    46. Saliba RM, Couriel D, Komanduri K, Patah P, Westin J, Giralt S, Cooper L, Petropoulos D, Worth L, Safdar A, Champlin RE, Shpall EJ, de Lima M (2008). Incidence and Risk Factors for Chronic Graft-Versus-Host Disease (cGVHD) after Cord Blood Transplantation (CBT) [Abstract]. Biol Blood Marrow Transplant, 14(2), 132-3.
    47. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, Khouri IF (2007). Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center [Abstract]. Blood, 110(11), 484.
    48. Qazilbash MH, Saliba RM, Parikh G, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin RE, Giralt S (2007). Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma [Abstract]. Blood, 110(11), 942.
    49. Patah P, Saliba R, Fernandez-Vina M, Cano P, Pesoa S, Rondon G, Andersson B, Giralt S, Kebriaei P, Hosing C, Anderlini P, Couriel D, Alousi A, Padua L, Ramos C, Champlin R, de Lima M (2007). A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants [Abstract]. Blood, 110(11), 3051.
    50. Khouri IF, Saliba RM, Korbling M, Hosing C, Fayad L, Lee MS, Samaniego F, Samuels BI, Couriel D, Hagemeister F, McLaughlin P, Champlin RE (2007). Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up [Abstract]. Blood, 110(11), 485.
    51. Couriel D, Patah P, Saliba R, Cooper L, Worth L, Petropoulos D, Depadua L, Zhang W, Giralt S, Champlin R, Shpall EJ, de Lima M (2007). Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes [Abstract]. Blood, 110(11), 2977.
    52. de Lima M, Andersson B, Fernadez-Vina M, Giralt S, Couriel D, Shpall E, Popat U, Qazilbash M, Alousi A, Cano P, Bosque D, Hosing C, Qureshi S, de Padua L, Munsell M, Anderlini P, Jones R, Westmoreland M, Gulbis A, Champlin R (2007). Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and "Mini"-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation [Abstract]. Blood, 110(11), 40.
    53. Westin JR, Saliba RM, de Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Champlin R, Couriel DR (2007). Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD) [Abstract]. Blood, 110(11), 5015.
    54. Komanduri KV, St John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Hosing C, Couriel D, de Lima M, Shpall EJ (2007). 20: Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized By Thymic Regeneration Failure [Abstract]. Biol Blood Marrow Transplant, 13(11), 1400.
    55. de Lima M, Patah PA, Saliba R, Couriel D, Chan K, Worth L, Giralt S, Kebriae P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri KV, Champlin RE, Shpall EJ (2007). 2: Donor-Recipient Host-Versus-Graft Human Leukocyte Antigen Mismatches and Outcome of Cord Blood Transplants [Abstract]. Biol Blood Marrow Transplant, 13(11), 1393.
    56. Gulbis AM, Hsu Y, Neumann JL, Hymes S, Lima MJd, Hosing CM, Khouri IF, Qazilbash MH, Kebriaei P, Andersson BS, Champlin RE, Couriel D (2007). 296: Etanercept as salvage therapy for chronic graft-versus-host disease [Abstract]. Biol Blood Marrow Transplant, 13(2 suppl), 107-8.
    57. Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q (2007). 309: Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation [Abstract]. Biol Blood Marrow Transplant, 13(2), 112-3.
    58. Trevino CM, Neumann J, Couriel D, Popat U, Hsu Y (2007). 419: Establishment of a long-term allogeneic blood and marrow program for early detection of complication and measuring outcomes [Abstract]. Biol Blood Marrow Transplant, 13(2), 149-50.
    59. Saliba RM, Komanduri K, Giralt S, Souza Jd, Patah PA, Oran B, Rondon G, Couriel D, Champlin R, Lima MD (2007). 269: Correlates and outcome of absolute lymphocyte count (ALC) on day 30 post allogeneic stem cell transplantation (SCT) for treatment of AML [Abstract]. Biol Blood Marrow Transplant, 13(2, suppl), 98.
    60. Qazilbash MH, Jindani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel D, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt SA (2007). 19: Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 13(2, suppl), 9-10.
    61. Qazilbash MH, Gul Z, Jindani S, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel D, de Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA (2007). 20: Autologous stem cell transplantation for elderly patients with multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 13(2, suppl), 10.
    62. Ahmed B, Saliba RM, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH (2006). Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant [Abstract]. Blood, 108(11), 3101.
    63. Anderlini P, Saliba RM, Acholonu S, Giralt SA, Khouri IF, Andersson B, De Lima M, Hosing C, Couriel D, Champlin RE (2006). Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin's Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors [Abstract]. Blood, 108(11), 3115.
    64. de Lima M, Parmar S, Liu P, Patah PA, Cano P, Shpall EJ, Hosing C, Couriel D, Anderlini P, Giralt S, Andersson BS, Kebriaei P, Rondon G, Champlin R, Fernandez-Vina M (2006). HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT) [Abstract]. Blood, 108(11), 3125.
    65. de Lima M, Patah PA, Saliba R, Couriel D, Chan K, Worth L, Giralt S, Kebriae P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri KV, Champlin RE, Shpall EJ (2006). Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT) [Abstract]. Blood, 108(11), 436.
    66. 116 de Lima M, Wang X, Thall PF, Couriel D, Jones RB, Shpall EJ, Popat U, Giralt S, Korbling M, Champlin R, Andersson BS (2006). Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS [Abstract]. Blood, 108(11), 322.
    67. Hosing C, Saliba RM, Okoroji G-J, Popat U, Couriel D, Kebriaei P, Ali T, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I (2006). High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin's Lymphoma (NHL) in Patients over 65 Years of Age [Abstract]. Blood, 108(11), 3059.
    68. Kebriaei P, Detry M, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri I, Anderlini P, Hosing C, Alousi A, Giralt S, Champlin R, de Lima M (2006). Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML) [Abstract]. Blood, 108(11), 2898.
    69. Kebriaei P, Giralt S, Madden TL, Thapar N, Shpall EJ, Hosing C, Qazilbash MH, Couriel DR, Popat U, Thall PF, Champlin RE, Jones R, Andersson BS (108). Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM) [Abstract]. Blood, 108(11), 2943.
    70. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji G-J, Stachowiak AM, Samuels BI, Anderlini P, Couriel DR, de Lima M, Giralt S, Popat U, Kebriaei P, Ueno NT, Qazilbash MH, McLaughlin PW, Hagemeister FB, Younes A, Podoloff DA, Champlin RE (2006). Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL) [Abstract]. Blood, 108(11), 315.
    71. Komanduri KV, St John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Couriel DR, de Lima M, Shpall EJ (2006). Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure [Abstract]. Blood, 108(11), 312.
    72. Patah PA, Gurkan E, Saliba R, de Lima M, Rondon G, Ramos CA, Couriel D, de Souza JA, Champlin R, Lichtiger B (2006). "Prophylactic" Platelet (PLT) Transfusions in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): Similar Clinical Efficacy of Single Donor (SDP) and Random Donor Pooled (RDP) Platelet Products [Abstract]. Blood, 108(11), 597.
    73. Qazilbash MH, Saliba R, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA (108). Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma [Abstract]. Blood, 108(11), 5422.
    74. Qazilbash MH, Saliba RM, Davis MS, Mendoza FL, Hosing C, Couriel DR, De Lima M, Kebriaei P, Weber DM, Wang M, Alousi AM, Matthes SG, Jones RB, Champlin RE, Giralt SA (2006). Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma [Abstract]. Blood, 108(11), 3090.
    75. Saliba RM, Khouri IF, de Lima M, Hosing C, Okoroji G, Acholonou S, Maadani F, De Jesus J, Hsu Y, Champlin RE, Couriel DR (2006). Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin's Lymphoma [Abstract]. Blood, 108(11), 5316.
    76. Kim SK, Couriel D, Ghosh S, Champlin R (2006). Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of stage III and IV ocular GVHD [Abstract]. Biol Blood Marrow Transplant, 12(2), 49-50.
    77. Couriel DR, Saliba RM, Ghosh S, Lima Md, Giralt S, Khouri I, Andersson B, Mickler K, Caldera Z, Hsu Y, Neumann J, Hymes S, Kim S, Champlin R (2006). Chronic or acute? GVHD beyond day 100 [Abstract]. Biol Blood Marrow Transplant, 12(2), 59.
    78. Mickler KL, Saliba R, Ghosh S, Lima Md, Giralt S, Kim S, Andersson B, Khouri I, Champlin RE, Couriel D (2006). The risk of Graft-Versus-Host Disease (GVHD) varies with different myeloablative regimens: IV Busulfan/Fludarabine (IV BuFlu) versus IV Busulfan/Cyclophosphamide (IV BuCy) versus Fludarabine/Melphalan (FM) [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 156-7.
    79. Neumann JL, Trevino CM, Hsu Y, Popat U, Champlin RE, Couriel D (2006). Establishment of a long-term allogeneic blood and marrow follow-up program for early detection of complications and measuring outcomes [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 164-5.
    80. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, DeLima M, Champlin RE, Giralt SA (2006). Salvage autologous transplantation in multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 121-2.
    81. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, Lima MD, Champlin RE, Giralt SA (2006). Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 117.
    82. Popat UR, de Lima M, Anderlini P, Andersson B, Couriel D, Hosing C, Kebriaei P, Qazilbash M, Alousi A, Champlin R, Giralt S (2006). Long-term survival of patients with AML in remission after reduced intensity allogeneic hematopoietic stem cell transplantation (RISCT) [Abstract]. ASH Clinical Science Symposium.
    83. de Lima M, Giralt S, Caldera Z, McCormick G, Qazilbash M, Anderlini P, Shpall EJ, Hosing C, Donato M, Kornblau S, Khouri I, Martin T, Couriel D, Champlin R (2005). Results of a phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for relapsed myeloid leukemias [Abstract]. Blood, 106(11), 941.
    84. de Lima M, Couriel DR, Ghosh S, Jones R, Shpall EJ, Giralt S, Hosing C, Kebriaei P, Champlin R, Andersson BS (2005). Outcomes of older patients with myeloid leukemias treated with myeloablative intravenous busulfan – based conditioning [Abstract]. Blood, 106(11), 660.
    85. Oran B, Giralt S, Shahjahan M, Anagnostopoulos A, Couriel D, Kebriaei P, Hosing C, Ghosh s, de Meis E, Donato M, Ativitavas T, Carrasco-Yalen A, Champlin R, de Lima M (2005). Natural history of AML/MDS relapsing after allogeneic hematopoietic stem cell transplantation using reduced intensity preparative regimens [Abstract]. Blood, 106(11), 2019.
    86. Oran B, Saliba R, Giralt S, Couriel DR, Carrasco-Yalan A, Hosing c, Shahjahan M, de Meis E, Anagnostopoulos A, Anderlini P, Gosh S, Khouri I, Champlin R, de Lima M (2005). Long-term follow up of allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan reduced intensity conditioning for high rick AML/MDS [Abstract]. Blood, 106(11), 838.
    87. Parmar S, Fernandez-Vina M, Liu P, Cano P, Andersson BS, Munsell M, Giralt S, McMannis J, Shpall EJ, Couriel D, Gosh S, Champlin R, de Lima M (2005). Influence of allele level HLA typing on unrelated donor transplantation for high risk myeloid leukamias [Abstract]. Blood, 106(11), 2916.
    88. Jabbour E, Shahjahan M, Rondon G, Anderlini P, Giralt S, Couriel DR, Champlin R, Khouri I (2005). Treatment of Graft Failure with Fludarabine, Antithymocyte Globulin and a Second Allogeneic Stem Cell Transplantation [Abstract]. Blood, 106(11), 2734.
    89. Hosing C, Saliba RM, de Lima M, Giralt S, Ghosh S, Hsu Y, Anderlini P, Hymes S, Andersson B, Khouri I, Champlin R, Couriel DR (2005). Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors [Abstract]. Blood, 106(11), 1123.
    90. Khouri IF, Tarrand JJ, Okoroji GJ, Salia RM, Hosing CM, Couriel DR, Kebriaei P, Friggith D, Rondon G, Ippoliti C, Champlin RE (2005). Campath-IH combined with fludarabine/cyclophosphamide/rituximab (FCR) as conditioning for unrelated non-myeloablative hematopoietic transplantation (NMT) for non-hodgkin’s lymphoma (NHL): Low mortality rate and lower than expected incidence of cytomegalovirus (CMB) reactivation [Abstract]. Blood, 106(11), 2902.
    91. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri I (2005). The impact of reituximab in the development of acute graft versus host disease (GVHD) following allogeneic stem cell transplantation (SCT) for acute lymphoblastic leukemia (ALL) [Abstract]. Blood, 106(11), 1803.
    92. Couriel DR, Thall P, Mickler K, de Lima M, Giralt S, Qazilbash MH, Hosing C, Khouri I, Kebriaei P, Hsu Y, Saliba R, Ippoliti C, Champlin R (2005). Phase II/III randomized study comparing two different tacrolimus blood levels for the prevention of graft-versus-host disease (GVHD) [Abstract]. Blood, 106(11), 142.
    93. Qazilbash MH, Davis MS, Aleman A, Roden L, Libuano F, Thall PF, Wang X, Couriel D, de Lima M, Hosing C, Kebriaei P, Weber D, Wang M, Jones RB, Matthes SG, Champlin RE, Giralt S (2005). Arsenic trioxide with ascorbic acid and high-dose melphalan: A new preparative regiman for autologous hematopoietic stem cell transplantation for multiple myeloma [Abstract]. Blood, 106(11), 1159.
    94. Saliba RM, de Lima M, Hosing C, Khouri IF, Giralt S, Anderlini P, Ghosh S, Mickler K, Ippoliti C, Caldera Z, Hsu Y, Neumann J, Champlin R, Couriel DR (2005). Clinical, prognostic and therapeutic implications in the diagnosis of grade I acute graft-versus-host disease [Abstract]. Blood, 106(11), 1799.
    95. Couriel DR, Saliba R, de Lima MJ, Hosing C, Andersson B, De Jesus J, Mickler K, Hsu Y, Shpall EJ, Neumann J, Ghosh S, Champlin R (2005). Hyperacute GVHD: Analysis of Risk Factors, Clinical Manifestations, and Outcomes [Abstract]. Biol Blood and Marrow Transplant, 11(2), 11.
    96. Alamo JG, Shahjahan M, Wong RS, de Lima M, Khouri I, Gajewski J, Couriel DR, Andersson, BS, Anderlini P, Champlin R, Giralt S (2005). Prognostic Factors for Allogeneic Stem Cell Transplantation (ASCT) for Untreated First Relapse of Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) [Abstract]. Biol Blood and Marrow Transplant, 11(2), 38-9.
    97. Couriel DR, Hosing C, Anderlini P, Ippoliti C, Hsu Y, Neumann J, de Lima MJ, Ghosh S, Rhodes B, Saliba R, Champlin R, Donato M (2005). Extracorporeal Photochemotherapy (ECP) for the Treatment of Chronic Graft-versus-Host Disease [Abstract]. Biol Blood and Marrow Transplan, 11(2), 48.
    98. de Lima M, Couriel DR, Shahjahan M, Alamo J, Madden T, Thapar N, Russell J, Anderlini P, Giralt S, Shpall E, Jones R, Champlin R, Andersson B (2005). Pretransplant Conditioning with IV Busulfan (BU) and Fludarabine (FLU) as Alternative to BU and Cyclophosphamide (CY)—A Safe, Myeloablative Regimen with High Antileukemic Efficacy in AML/MDS [Abstract]. Biol Blood and Marrow Transplant, 11(2), 63.
    99. Thall PF, Wooten LH, Couriel DR, Champlin RE (2005). An Adaptive Bayesian Design for a Randomized Trial of High-Versus-Low-Level Tacrolimus as Prophylaxis for Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation [Abstract]. Biol Blood and Marrow Transplant, 11(2), 107.
    100. Escalon MP, Saliba RM, Hsu Y, Ghosh S, Ippoliti C, Hosing C, de Lima MJ, Neumann JL, Champlin RE, Couriel DR (2005). Sirolimus in combination with tacrolimus for the treatment of resistant chronic graft-versus-host disease [Abstract]. J Clin Oncol, 23(16S), 599s.
    101. de Lima M, Couriel DR, Shahjahan M, Alamo J, Thall P, Russell J, Anderlini P, Giralt S, Shpall E, Jones R, Champlin R, Andersson B (2004). IV Busulfan (Bu) with Fludarabine (Flu) or Cyclophosphamide (Cy) – Comparing Ablative Conditioning Regimens for Allogeneic Transplantation in AML/MDS [Abstract]. Blood, 104(11), 30a-1a.
    102. Qazilbash M, Wieder E, Rios R, Lu S, Kant S, Giralt S, Estey E, Thall P, de Lima M, Couriel DR, Champlin R, Komanduri K, Molldrem J (2004). Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia [Abstract]. Blood, 104(11), 77a.
    103. de Lima M, Couriel DR, Munsell M, Westmoreland M, Shah H, deJesus J, Hosing C, Ghosh S, Anderlini P, Gajewski J, Andersson B, Kornblau S, Hocking B, Ippoliti C, Giralt S, Shpall E, Champlin R (2004). Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Propjylaxis: A Phase I/II Controlled, Randomized Study [Abstract]. Blood, 104(11), 208a.
    104. Couriel DR, Saliba R, de Lima M, Hosing C, Andersson B, deJesus J, Mickler K, Hsu Y, Shpall E, Ghosh, S, Champlin R (2004). Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes [Abstract]. Blood, 104(11), 210a.
    105. Shpall E, de Lima M, Chan K, Champlin R, Gee A, Thall P, Komanduri K, Couriel DR, Andersson B, Hosing C, Giralt S, Karandish S, Sadeghi T, Muriera B, Peled T, Grynspan F, Nagler A, McMannis J (2004). Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator [Abstract]. Blood, 104(11), 281a.
    106. de Lima M, Thall P, Shahjahan M, Xuemei W, Couriel DR, Anderlini P, Hosing C, Qazilbash M, McCormick G, Ippoliti C, Donato M, Martin T, Metoyer L, Griffin L, Kebriaei, P, Champlin R, Giralt S (2004). Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regiment for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS [Abstract]. Blood, 104(11), 505a.
    107. de Lima M, Shahjahan M, Alamo J, Williams, P, von Wolff B, Couriel DR, Khouri I, Rondon G, Wheeler B, Estey E, Ueno N, Kebriaei P, Champlin R, Giralt S (2004). Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS [Abstract]. Blood, 104(11), 632a.
    108. Qazilbash M, Saliba R, de Lima M, Couriel DR, Hosing C, Aleman A, Lei X, Champlin R, Giralt S (2004). Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma [Abstract]. Blood, 104(11), 909a.
    109. Khouri I, Saliba R, Couriel DR, Okoroji G, Acholonu S, Maadani F, Champlin R (2004). Effect of Rituximab on the Incidence of GVHD in Lymphoma Patients Who Received the BEAM-Conditioning and an Allogeneic Stem Cell Transplantation [Abstract]. Blood, 104(11), 326b.
    110. Khouri I, Saliba R, Kebriaei P, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash M, Gajewski J, Champlin R (2004). Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H [Abstract]. Blood, 104(11), 366b.
    111. De Jesus J, Ghosh S, Hsu Y, Neumann J, Cohen A, Champlin R, Couriel DR (2004). Tacrolimus in combination with steroids for the treatment of chronic GvHD [Abstract]. Biol Blood and Marrow Transplant, 10(2), 49-50.
    112. Cheng YCC, Rondon G, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Gajewski JL, Champlin RE, Ueno NT (2004). Interleukin-2 (IL-2) with high-dose chemotherapy (HDC) and autologous hematopoietic stem-cell transplantation (AHST) for poor-risk metastatic breast cancer (MBC) [Abstract]. J Clin Oncol, 23, 6664.
    113. de Lima M, Saliba R, Carrasco A, Shahjahan M, Couriel DR, Anagnostopoulos A, Hosing C, Shah H, de Meis E, Champlin R, Giralt S (2003). Long-Term Follow-up Of Patients with AML and MDS treated with Reduced-Intensity (RI) or Non-Myeloablative (NMA) conditioning regimens and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [Abstract]. Blood, 102(11), 724a.
    114. Anderlini P, Acholonu S, Okoroji GJ, Giralt S, Ueno N, Donato M, Andersson BS, Khouri I, Couriel DR, Ippoliti C, Valverde RB, Champlin R (2003). Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin’s Disease (HD) [Abstract]. Biol Blood and Marrow Transplant, 9(2), 71.
    115. Lee B, Couriel DR, Shen D, Hinze L, Champlin R, Reuben JM (2003). Serum Cytokine Profiles of Patients with Acute GvHD treated with Methylprednisolone alone or in combination with Infliximad are different [Abstract]. Biol Blood and Marrow Transplant, 9(2), 98-9.
    116. Neumann JL, Hsu Y, Tallarigo J, Champlin R, Couriel DR (2003). Quality of life in patients with chronic GvHD: A quality process improvement in blood and marrow transplantation [Abstract]. Biol Blood and Marrow Transplant, 9(2), 119.
    117. Couriel DR, Hicks K, Saliba R, Cohen A, Ippoliti C, Hsu Y, Donato M, Giralt S, Khouri I, Hosing C, De Lima MJ, Andersson B, Gajewski J, Neumann J, Champlin R (2003). Sirolimus(Rapamycin) for treatment of Steroid-refractory chronic GvHD [Abstract]. Biol Blood and Marrow Transplant, 9(2), 67-8.
    118. Couriel DR, Hicks K, Giralt S, Ippoliti C, Khouri I, De Lima M, Horton E, Cohen A, Hosing C, Donato M, Anderlini P, Molldrem JJ, Gajewski J, Champlin R (2003). Phase III Trial with Infliximab/methypredisolone (MP) vs. MP for the treatment of acute GvHD: Preliminary findings [Abstract]. Biol Blood and Marrow Transplant, 9(2), 95.
    119. Hicks K, Ippoliti C, Giralt S, de Lima MJ, Cohen A, Donato M, Khouri I, Champlin R, Couriel DR (2003). Predominance of resistant gram positive isolates as sources of bacteremia in GvHD patients treated with Infleximab [Abstract]. Biol Blood and Marrow Transplant, 9(2), 133.
    120. de Lima M, Carrasco A, Lee MS, Saliba R, Glassman A, Anagnostopoulos A, Couriel DR, Caldera H, Andersson BS, El-Zimaity M, Giralt S, Champlin R (2003). Mixed chimerism after allogeneic hematopoietic stem cell transplantation (hsct) for acute myeloid leukemia (aml) and myelodysplastic syndrome (mds) [Abstract]. Blood, 102(11), 707a.
    121. El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel DR, Ippoliti C, Hosing C, Champlin R, de Lima M (2003). Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: Donor type matters [Abstract]. Blood, 102(11), 432b.
    122. de Lima M, Madden T, Couriel DR, Thall PF, Shahjahan M, Giralt S, Anderlini P, Russell J, Shpall EJ, Champlin RE, Andersson BS (2003). Once daily busulfan (Bu) and fludarabine (FLU) with allogeneic stem cell transplantation (AlloSCT) in acute myelogenous leukemia (AML) and myelodysplastics syndrome (MDS): Clinical results and pharmacokinetics [Abstract]. Blood, 102(11), 704a.
    123. Couriel DR, Carrasco A, Saliba R, Ghosh S, De Lima M, Hosing C, Khouri I, Andersson B, Champlin R, Cleary K (2003). GvHD of the Liver: A Clinicopathological Analysis [Abstract]. Blood, 102(11), 712a.
    124. Couriel DR, Saliba R, Ghosh S, de Lima M, Hosing C, Khouri I, Giralt S, Cohen A, Champlin RE (2003). Early Acute GVHD: Syndrome and Clinical Implications [Abstract]. Blood, 102(11), 712a.
    125. Khouri IF, Saliba RM, Acholonu S, Okoroji GJ, Hosing C, Fayad L, Couriel DR, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin RE (2003). Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas (NHL): The Impact of Histologies of Follicular (FL) Origin [Abstract]. Blood, 102(11), 735a.
    126. Espirito J, Hicks KL, Ghosh S, Couriel DR (2003). Evaluation of the Use of Synagis (Palivizumab) for Treatment of Respiratory Syncytial Virus Infection in Bone Marrow Transplant Recipients [Abstract]. Blood, 102(11), 973a.
    127. Madden T, Nguyen J, Thapar N, Couriel DR, de Lima M, Pierre B, Espinosa L, Champlin RE, Andersson B (2003). The Pharmacokinetics (PK) of Once Daily Intravenous (IV) Busulfan (Bu) as Part of Pre-transplant Preparative Regimens; a Comparison to Q 6 Hourly Dosing [Abstract]. Blood, 102(11), 477a.
    128. Lee BN, Andersson V, Cohen MZ, Mendoza T, de Lima M, Couriel DR, Brown BW, Wang XS, Cleeland CS, Giralt S, Champlin RE, Reuben JM (2003). Relationship between Plasma Cytokine Levels and Self-Reported Symptoms in AML Patients Pre-and Post-Transplantation with Allogeneic Peripheral Blood Stem Cells [Abstract]. Blood, 102(11), 966a.
    129. Hsu Y, Cohen A, Couriel DR (2003). Eosinophilia as a Presenting Sign for Chronic Graft Versus Host Disease after Allogeneic Bone Marrow Transplantation [Abstract]. Blood, 102(11), 462b.
    130. Kim SK, Couriel DR, Combos D, Esmaeli B (2003). Early topical steroid treatment for grade IV acute ocular graft-vs-host disease (GVHD) with corneal epithelial sloughing [Abstract]. Investigative Ophthalmology and Visual Science, 44, 1387S.
    131. Anderlini P, Acholonu S, Okoroji G, Giralt S, Ueno N, Donato M, Andersson B, Khouri I, Couriel DR, Champlin RE (2003). Fludarabine-based, reduced intensity conditioning allows minimal early transplant related mortality following allogeneic stem cell transplantation from matched related and unrelated donors in advanced Hodgkin’s disease [Abstract]. Experimental Hematology, 31(7), 25S.
    132. Gajewski J, Cano P, Saliba R, Giralt S, Khouri I, Ma Y, Shahjahan M, Couriel DR, Andersson B, Champlin RE (2003). Impact of allele level molecular HLA typing on non-myeloablative unrelated donor bone marrow transplants [Abstract]. Experimental Hematology, 31(7), 28S.
    133. de Lima M, Shahjahan M, Madden T, Couriel DR, Gajewski JL, Giralt S, Donato ML, Russell JA, Champlin RE, Andersson BS (2002). Reduced toxicity conditioning therapy with fludarabine and IV busulfan ATG for allogeneic transplantation in AML and MDS; preliminary results [Abstract]. Biol Blood and Marrow Transplant, 8(2), 76.
    134. Wong R, Hicks K, Ippoliti C, Giralt S, de Lima M, Cohen A, Khouri I, Champlin R, Couriel DR (2002). Tumor necrosis factor alpha blockade in the treatment of graft-versus-host disease: an update on infectious complications [Abstract]. Biol Blood and Marrow Transplant, 8(2), 91.
    135. Couriel DR, Giralt S, Khouri I, Andersson B, Cohen A, de Lima M, Saliba R, Champlin R (2002). Graft-versus-host disease (GvHD) after non-myeloablative (NMA) vs myeloablative (MA) conditioning in fully matched sibling donor transplants: An update [Abstract]. Biol Blood and Marrow Transplant, 8(2), 85.
    136. Couriel DR, Hicks K, Ippoliti C, de Lima M, Donato M, Cohen A, Andersson B, Hosing C, Giralt S, Champlin R (2002). Tumor necrosis factor alpha blockage with infliximab in the treatment of acute graft-versus host disease (GvHD): An update [Abstract]. Biol Blood and Marrow Transplant, 8(2), 85.
    137. Gajewski JL, Khouri I, Champlin RE, Saliba RM, McMannis JD, Donato ML, Ueno N, Couriel DR, Shahjahan M, Ma Y, Giralt SA (2002). Anti-thymocyte globulin (ATG) reduces primary graft failure (GF) risk and may reduce acute graft versus hot disease (aGvHD) in 212 non-myeloablative blood and marrow transplant (BMT) patients (pts) receiving unrelated or 1 antigen (Ag) mismatched (MM) related donor grafts [Abstract]. J Clin Oncol, 21, 1676.
    138. Madden T, de Lima M, Shahjahan M, Pierre B, Gajewski JL, Giralt S, Donato ML, Russell JA, Champlin RE, Andersson BS, Couriel DR (2002). Pharmacokinetics of once daily IV Busulfan in a myeloablative/reduced toxicity conditioning regimen for allogeneic transplantation in myeloid leukemia [Abstract]. Second International Conference on High Dose Chemotherapy Innovation and Evolution.
    139. Couriel DR, Hicks K, Saliba R, Cohen A, Ippoliti C, Donato M, Anderlini P, Giralt S, Khouri I, Hosing C, de Lima M, Andersson B, Neumann J, Champlin R (2002). Sirolimus (Rapamycin) for treatment of steroid-refractory chronic graft versus host disease [Abstract]. Blood, 100(11), 847a.
    140. Couriel DR, Saliba R, Hicks K, Cohen A, Ippoliti C, Neumann J, Giralt, S, de Lima M, Champlin R (2002). TNF-alpha inhibition for the treatment of chronic GvHD [Abstract]. Blood, 100(11), 847a.
    141. Hosing C, de Lima M, Saliba RM, Shahjahan M, Couriel DR, Andersson B, Giralt S, Champlin RE (2002). Second allogeneic hematopoietic stem cell transplantation (HSCT) in patients with refractory hematopoietic malignancies [Abstract]. Blood, 100(11), 430a, 1666.
    142. Khouri I, Sheng LM, Saliba R, Jun G, Fayad L, Hosing C, Donato M, Pro B, Couriel DR, Rodriguez M, Krbling M, Cabanillas F, Ruth K, Champlin R (2002). Nonablative allogeneic stem cell transplantation for relapsed mantle cell lymphoma (MCL): A promising strategy for an aggressive disease [Abstract]. Blood, 100(1), 426a-7a.
    143. Gajewski J, Cano P, Saliba RM, Khouri I, Giralt S, Ma Y, Shahjahan M, Couriel DR, Andersson B, Champlin R (2002). Impact of high resolution molecular HLA typing and ATG on outcomes of non-myeloablative unrelated donor Bone Marrow Transplantation [Abstract]. Blood, 100(11), 466b.
    144. de Lima M, Wong R, Martin T, Couriel DR, Anagnostopoulos A, Shahjahan M, Hosing C, Andersson B, Donato M, Cano P, Ippoliti C, Estey E, Gajewski J, Champlin R, Giralt S (2002). Unrelated donor hematopoietic stem cell transplantation (HSCT) for the treatment of myeloid malignancies in patients older than 55 years of age [Abstract]. Blood, 100(1), 642a.
    145. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, de Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Youness A, McLaughlin P, Champlin RE (2002). Concurrent administration of high- dose rituximab (HD-R) with G/GM-CSF and autologous Stem cell Transplantation for relapsed B cell lymphomas: Increased efficacy without added toxicity [Abstract]. Blood, 100(11), 645a.
    146. Khouri IF, Lee MS, Saliba RM, Gu J, Fayad L, Hosting C, Donato ML, Pro B, Couriel DR, Rodriguez M, Korbling M, Cabanillas F, Ruth K, Champlin RE (2002). Nonablative allogeneic stem cell transplantation for relapsed mantle cell lymphoma (MCL): A promising strategy for an aggressive disease [Abstract]. Blood, 100(11), 1652.
    147. Anderlini P, Acholonu S, Okoroji GJ, Giralt S, Ueno N, Donato M, Andersson BS, Khouri I, Couriel DR, Ippoliti C, Valverde RB, Champlin RE (2002). Reduced early transplant-related mortality following allogeneic stem cell transplantation with fludarabine based, reduced intensity conditioning from matched related and unrelated donors in advanced Hodgkin’s disease [Abstract]. Blood, 100(11), 620a, 2444.
    148. Anagnostopoulos A, de Lima M, Munsell M, Shahjahan M, Couriel DR, Martin T, Cano P, McMannis J, Gajewski J, Andersson B, Champlin RE, Giralt S (2002). Unrelated donor bone marrow transplantation (UDR) for adults with AML/MDA: Similar outcomes with ablative or reduced intensity preparative regimens [Abstract]. Blood, 100(11), 635a-6a, 2502.
    149. de Lima, M, Wong R, Martin T, Couriel DR, Anagnostopoulos A, Shahjahan M, Hosing C, Andersson B, Donato M, Cano P, Ippoliti C, Estey E, Gajewski J, Champlin RE, Giralt S (2002). Unrelated donor hematopoietic stem cell transplantation (HSCT) for the treatment or myeloid malignancies in patients older than 55 years of age [Abstract]. Blood, 100(11), 2526.
    150. de Lima M, Couriel DR, Shahjahan M, Madden T, Gajewski J, Giralt S, Russell J, Champlin RE, Andersson BS (2002). Allogeneic transplantation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using a low-toxicity combination of intravenous (IV) Busulfan (Bu) and Fludarabine (Flu) +/- ATG [Abstract]. Blood, 100(11), 853a, 3366.
    151. de Lima M, Saliba RM, Ma C, Shahjahan M, Giralt S, Donato M, Couriel DR, Khouri I, de Meis E, Andersson BS, Champlin RE, Gajewski J (2002). Analysis of one antigen mismatched related transplants for advanced stage myeloid leukemias [Abstract]. Blood, 100(11), 857a, 3380.
    152. Andersson B, Madden T, Shahjahan M, de Lima M, Couriel DR, Gajewski J, Giralt S, Donato M, Russell J, Champlin RE (2002). Early data using fludarabine and IV busulfan ATG as myeloablative, yet reduced toxicity conditioning regimen for allogeneic transplantation in AML and MDS [Abstract]. Bone Marrow Transplantation, 29(S2), 75s.
    153. Andersson BS, Thall PF, Madden T, Couriel DR, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE (2001). Busulfan systemic exposure after the IVBuCy2 regimen correlates with acute Graft versus Host Disease and toxicity after Stem Cell Transplantation for CML [Abstract]. Bone Marrow Transplantation, 27, S185.
    154. Couriel DR, Hartzog MG, Sadeghi TH, Esfandiary N, Cohen AI, de Lima M, Giralt SA, Gajewski JL, Champlin RE, Andersson BS (2001). Conditioning regimen and graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT): Intravenous Busulfan/Cyclophosphamide (BU/CY) vs total body irradiation (TBI) [Abstract]. Bone Marrow Transplant, 7, 69.
    155. de Lima M, Shahjahan M, Madden T, Tran HT, Gajewski JL, Couriel DR, Giralt S, Donato ML, Anderlini P, Krbling M, Khouri I, Russell JA, Champlin RE, Andersson BS (2001). Fludarabine (Flu) and IV Busulfan (BU)± ATG: Low toxicity conditioning regimen for stem cell transplantation (SCT) in AML and MDA – Preliminary Results [Abstract]. Blood, 98(11), 345b.
    156. Couriel DR, Khouri IF, Andersson BS, Cohen A, Saliba R, de Lima M, Martin T, Giralt S, Champlin RE (2001). Graft-versus-host-disease (GvHD) after non-myeloablative (NMA) versus myeloablative (MA) conditioning regiments in fully matched sibling donor hematopoietic stem cell transplants (HSCT): An Update [Abstract]. Blood, 98(11), 404a.
    157. Couriel DR, Saliba R, Cohen A, Rondon G, Horton E, de Lima M, Martin T, Ippoliti C, Khouri IF, Gajewski JL, Giralt S, Champlin RE (2001). Selection of patients for antihymocyte globulin (ATG) treatment in steroid refractory acute (GVHD (SR aGVHD): Favorable response in isolated skin or GI involvement [Abstract]. Blood, 98(11), 355b.
    158. Khouri IF, Saliba RM, Giralt S, Okoroji GJ, Younes A, Fayad L, Korbling M, Rodriguez MA, Couriel DR, Bibawi S, Hosing C, McMannis J, Cabanillas F, Champlin RE (2001). Long-term remission and low mortality Cisplatin, Fludarabine, Cytarabine nonablative preparative regimen and allogeneic stem transplantation (AST) for histologically aggressive Non-Hodgkin’s Lymphoma [Abstract]. Blood, 98(11), 190a.
    159. Khouri IF, Saliba R, Lee MS, Giralt S, Younes A, Couriel DR, Fayad L, de Lima M, Hagemeister FB, Housing C, McLaughlin P, Ueno N, Rodriguez MA, Korbling M, Gajewski J, Cabanillas F, Champlin RE (2001). Nonablative allogeneic stem cell transplantation (AST) for Non-Hodgkin’s lymphoma (NHL): improved outcome with low incidence of acute GvHD and treatment related mortality [Abstract]. Blood, 98, 1746a.
    160. Hartzog MG, Sadeghi TK, Couriel DR, Esfandiary N, Giralt SA, Khouri IF, Gajewski JL, Champlin RE, Andersson BS (2001). Hematopoietic stem cell transplantation (HSCT) for CML after IV busulfan/cyclophosphamide (IV BU/CY) vs thiotepa cytosan total body irradiation (TT-CY-TBI) [Abstract]. Proceedings American Association of Cancer Research 2900, 539.
    161. de Lima M, Komanduri K, St John L, Wieder E, Lee M, McMannis J, Karandish S, Giralt S, Beran M, Couriel DR, Korbling M, Martin T, Andersson B, Bibawi S, Westmoreland M, Hosing C, Champlin RE (2001). Using two mismatched unrelated donor cord blood units for transplantation: analysis of chimerism and immune reconstitution [Abstract]. Blood, 98(11), 382b, 5308.
    162. Gajewski J, Khouri I, Champlin RE, Saliba R, McMannis JD, Donato M, Ueno N, Couriel DR, Bibawi S, Shahjahan M, Ma Y, Giralt S (2001). Anti-thymocyte globulin (ATG) reduces risk of primary graft failure and many reduce acute graft versus host disease (aGvHD) in 212 non-myeloablative blood and marrow transplant (BMT) patients (pts) receiving unrelated or 1 antigen (Ag) mismatched (MM) related donor grafts [Abstract]. Blood, 98(11), 383b.
    163. Hosing C, de Lima M, Phan M, Martin T, Giralt S, Couriel DR, Hicks K, Ippoliti C, Donato M, Komanduri K, Champlin RE (2001). Hemorrhagic Cystitis after Mismatched Unrelated Cord Blood Transplantation for Adults [Abstract]. Blood, 98(11), 383b.
    164. Martin T, Shahjahan M, de Lima M, Couriel DR, Champlin R, Gajewski J, Giles F, Kantarjian H, Andersson B, Giralt S (2001). The use of mylotarg as anti-leukemia therapy increases the incidence of liver toxicity including VOD following allogeneic transplantation [Abstract]. Blood, 98(11), 190a.
    165. Couriel DR, Hicks K, Ippoliti C, Donato ML, Martin T, Anderlini P, Khouri I, Andersson B, Giralt S, Champlin RE (2000). Infliximab for the Treatment of Graft-Versus-Host Disease in Allogeneic Transplant Recipients [Abstract]. J Clin Oncol, 1952a.
    166. Couriel DR, Hicks K, Ippoliti C, de Lima M, Donato M, Martin T, Anderlini P, Khouri I, Andersson B, Giralt S, Champlin R (2000). Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: An Update [Abstract]. Blood, 96(11), 400a.
    167. Couriel DR, Giralt S, de Lima M, Esfandiary N, Martin T, Donato M, Hicks K, Andersson B, Champlin R (2000). Graft vs host disease (GVHD) after non-myeloablative (NMA) versus myeloablative (MA) conditioning regimens in fully matched sibling donor hematopoietic stem cell transplants (HSCT) [Abstract]. Blood, 96(11), 408a.
    168. Andersson B, Tran Hai T, Madden T, Esfandiary N, Gajewski J, Couriel DR, Giralt S, Donato M, Anderlini P, Krbling M, Khouri I, Kantarjian H, Champlin R (2000). Acute graft vs. host disease (aGvHD) and toxicity correlate with busulfan systemic exposure (Bu-SE) after the IV BuCy2 regimen and stem cell transplants (HSCT) for CML [Abstract]. Blood, 96(11), 393a.
    169. Colares M, de Lima M, Yazji S, Khouri I, Anderlini P, Donato M, Couriel DR, Giralt S, Martin T, Hosing C, Krbling M, Champlin R (2000). Outcome of autologous hematopoietic stem cell transplant (auto HSCT) for patients (pts) with non-Hodgkin’s lymphoma (NHL) that fail to mobilize autologous peripheral blood stem cells (PBSC) [Abstract]. Blood, 96(11), 795a.
    170. Barrett AJ, Mavroudis D, Molldrem J, Couriel DR, Young NS (1996). Immune Modulation to Treat Leukemic Relapse Following Allogeneic Bone Marrow Transplantation: A Risk-Based Sequential Approach [Abstract]. Blood, 88(10), 1026s.
    171. Barrett AJ, Dunbar C, Cottler-Fox M, Couriel DR (1995). T-Cell Depletion with Delayed Lymphocyte Add-Back to Reduce GVHD and Promote GVL in Patients Receiving HLA-Matched BMT for Leukemia and MDS [Abstract]. Bone Marrow Transplantation, 15(S2), 1995.
    172. Cottler-Fox M, Couriel DR, Dunbar C, Carter C, Yu M, Barrett AJ (1995). Counterflow Centrifugal Elutriation (CCE) of Bone Marrow Reveals Two Patterns of Hematopoietic Progenitor Stem Cell (HPSC) Distribution in Normal Donors [Abstract]. Blood, 86(10), 474s.
    173. Jiang YZ, Mavroudis DA, Dermime S, Hensel NF, Couriel DR, Molldrem J, Mahoney MH, Barrett AJ (1995). Exogenous Antigen Processing and Presentation with Induction of Cytotoxic CD4+ Lymphocytes by Chronic Myelogenous Leukemia Cells [Abstract]. Blood, 86(10), 618s.
    174. Dermime S, Molldrem J, Parker KC, Jiang YZ, Mavroudis D, Hensel N, Couriel DR, Mahoney M, Coligan JE, Barrett AJ (1995). Human CD8+ T Lymphocytes Recognize the Fusion Region of BCR/ABL Hybrid Protein Present in Chronic Myelogenous Leukemia [Abstract]. Blood, 86(10), 620s.
    175. Couriel DR, Canosa J, Engler H, Molldrem J, Mavroudis D, Dun Dunbar C, Collins A, Wesley B, Barrett AJ (1995). Factors Predicting Outcome Following Reactivation of Cytomegalovirus After T-Depleted BMT for Hematologic Malignancies [Abstract]. Blood, 86(10), 853s.
    176. Couriel DR, Mahoney M, Hensel N, Mavroudis D, Jiang YC, Dermime S, Molldrem J, Barrett AJ (1995). Donor-vs-Recipient Helper T Lymphocyte Precursor Numbers Given But Not Their Frequency Predicts GVHD in HLA Matched Sibling BMT [Abstract]. Blood, 86(10), 1575s.
    177. Molldrem J, Dermime S, Parker K, Couriel DR, Hensel N, Jiang YZ, Mavroudis D, Mahoney M, Barrett AJ (1995). Cytotoxic T Cells Show Specificity to MHC Class I-Restricted Peptide Derived from Proteinase 3, A Leukemia-Associated Protein [Abstract]. Blood, 86(10), 1695s.
    178. Mavroudis D, Jiang YZ, Hensel N, Couriel DR, Dermime S, Mahoney M, Barrett AJ (1995). Specific Depletion of Donor-vs-Recipient Alloreactivity to Prevent GVHD after Marrow Transplantation [Abstract]. Blood, 86(10), 2267s.
    179. Barrett AJ, Couriel DR, Dunbar C, Fox M, Young NS, OKunnief P (1995). Low Incidence of Acute GVHD Following Delayed T Cell Add-Back after T-Depleted BMT for Hematologic Malignancies [Abstract]. Blood, 86(10), 2463s.
    180. Couriel DR, Cottler-Fox M, Burt RK, Dunbar C, Hensel N, Young NS, Barrett AJ (1994). T-Cell-Depleted Marrow Transplants with Delayed Lymphocyte Add-Back to Prevent Relapse in Patients with Leukemia and MDS [Abstract]. Blood, 84(10), 334a.
    181. Mavroudis DA, Jiang YZ, Hensel, Couriel DR, Lewalle PA, Barrett AJ (1994). Selective T Cell Depletion to Prevent Graft Versus Host Disease (GVHD) in HLA Haplotype Mismatched Bone Marrow Transplantation (BMT) [Abstract]. Blood, 84(10), 737a.
    182. Jiang YZ, Couriel DR, Malkovska V, Lewalle PA, Mavroudis DA, Hensel NF, Barrett AJ (1994). HLA-DR1 Transfected K562 Cells Inhibit NK Cell Cytotoxicity [Abstract]. Blood, 84(10), 289a.
    183. Pandite L, Couriel DR, Weinstein R (1993). Storage of Hematopoietic Stem Cells at -80 C DMSO-free Cryoprotectant [Abstract]. Transfusion, 33(9), 73s.

    Other

    1. Zhou CChan HPDong QHe BWei JHadjiiski LMCouriel D (2014). Automated identification of spinal cord and vertebras on sagittal MRI. Zhou C|Chan HP|Dong Q|He B|Wei J|Hadjiiski LM|Couriel D (Ed.), Progress in Biomedical Optics and Imaging - Proceedings of SPIE (9035). (Read full article)
    2. Dai E, Couriel D, Kim SK (2007). Bilateral marginal keratitis associated with engraftment syndrome after hematopoietic stem cell transplantation. Cornea (26(6), pp. 756-8). United States. (Read full article)
    3. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ (2006). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (12(5), pp. 491-505). United States. (Read full article)
    4. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME (2006). Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (12(4), pp. 375-96). United States. (Read full article)
    5. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB (2006). Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (12(1), pp. 31-47). United States. (Read full article)
    6. Wong R, Durand JB, Luna MA, Couriel DR, Gajewski JL (2004). Images in cardiovascular medicine. Constrictive pericarditis in a patient with relapsed acute myelogenous leukemia after allogeneic bone marrow transplantation. Circulation (109(9), pp. e146-9). United States. (Read full article)

    Video/Film/CD/Web/Podcast

    1. Daniel R Couriel (2021). (2021) How to Reduce Toxicity from GVHD Treatment, Expert Perspectives in cGVHD, BioPharm Communications, Engage Health Media, Virtual Conference [Video]. Engage Health Media.
    2. Couriel DR (June 2009). Physician Educational Material, Videorecording: Clinical Aspects on the Treatment of Chronic GVHD with Extracorporeal Photopheresis [Video]. London, UK: Therakos, Inc..
    3. Couriel DR (March/April 2009). NOXAFIL®US Speaker-Training webcast session [Video]. Schering-Plough.